Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Assessment and management of resistant hypertension.

Literature DB >> 25135921

Assessment and management of resistant hypertension.

Raj S Padwal¹, Simon Rabkin², Nadia Khan².

Abstract

Entities: Disease

Mesh：

Substances：
Antihypertensive Agents

Year: 2014 PMID： 25135921 PMCID： PMC4259798 DOI： 10.1503/cmaj.130764

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

64 in total

1. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study.

Authors: Felix Mahfoud; Markus Schlaich; Ingrid Kindermann; Christian Ukena; Bodo Cremers; Mathias C Brandt; Uta C Hoppe; Oliver Vonend; Lars C Rump; Paul A Sobotka; Henry Krum; Murray Esler; Michael Böhm
Journal: Circulation Date: 2011-04-25 Impact factor: 29.690

2. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.

Authors: Stephen T Turner; Gary L Schwartz; Arlene B Chapman; Amber L Beitelshees; John G Gums; Rhonda M Cooper-DeHoff; Eric Boerwinkle; Julie A Johnson; Kent R Bailey
Journal: Am J Hypertens Date: 2010-08-19 Impact factor: 2.689

3. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

Authors: Murray D Esler; Henry Krum; Paul A Sobotka; Markus P Schlaich; Roland E Schmieder; Michael Böhm
Journal: Lancet Date: 2010-11-17 Impact factor: 79.321

4. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades.

Authors: Finlay A McAlister; Kathryn Wilkins; Michel Joffres; Frans H H Leenen; George Fodor; Marianne Gee; Mark S Tremblay; Robin Walker; Helen Johansen; Norm Campbell
Journal: CMAJ Date: 2011-05-16 Impact factor: 8.262

5. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.

Authors: Alejandro de la Sierra; Julián Segura; José R Banegas; Manuel Gorostidi; Juan J de la Cruz; Pedro Armario; Anna Oliveras; Luis M Ruilope
Journal: Hypertension Date: 2011-03-28 Impact factor: 10.190

6. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial.

Authors: Lourdes Lozano; José Luis Tovar; Gabriel Sampol; Odile Romero; María José Jurado; Alfons Segarra; Eugènia Espinel; José Ríos; María Dolores Untoria; Patrícia Lloberes
Journal: J Hypertens Date: 2010-10 Impact factor: 4.844

7. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.

Authors: Jan Václavík; Richard Sedlák; Martin Plachy; Karel Navrátil; Jirí Plásek; Jirí Jarkovsky; Tomás Václavík; Roman Husár; Eva Kociánová; Milos Táborsky
Journal: Hypertension Date: 2011-05-02 Impact factor: 10.190

Assessment and management of resistant hypertension.

1. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study.

2. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.

3. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

4. Changes in the rates of awareness, treatment and control of hypertension in Canada over the past two decades.

5. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring.

6. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial.

7. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.

8. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study.

9. Prevalence of resistant hypertension in the United States, 2003-2008.

Review 10. Prevalence and diagnosis of primary aldosteronism.

1. Management of resistant hypertension.

2. Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus.